The Virginia Tech-Wake Forest University Center for Injury Biomechanics has been awarded a $2.8 million contract from the U.S. Army Medical Research and Materiel Command for phase 2 of an overall project focusing on brain and eye injuries in military p…
Author: Medical News Today
Enzyme Inhibition Or Removal May Prevent Or Treat Ischemic Retinopathy
The inhibition or removal of an enzyme may prevent or treat ischemic retinopathy by stalling growth of unwanted vessels in the retina, Medical College of Georgia researchers say. Ischemic retinopathy is characterized by uncontrolled formation of new …
Scientific Evidence Supports Effectiveness Of Chinese Drug For Cataracts
Scientists are reporting a scientific basis for the long-standing belief that a widely used non-prescription drug in China and certain other countries can prevent and treat cataracts, a clouding of the lens of the eye that is a leading cause of vision…
CMA And CAEPS File Lawsuit To Block New Standards To Certify Optometrists To Treat Glaucoma
To ensure Californians afflicted with the eye disease glaucoma get appropriate medical treatment, the California Medical Association (CMA) and the California Academy of Eye Physicians and Surgeons (CAEPS) today filed a lawsuit in San Francisco Superior…
Study Sheds New Light On River Blindness Parasite
The team found that a bacterium inside the worm acts as a ‘disguise’ for the parasite, resulting in the immune system reacting to it in an ineffective way. The bacteria protect the worm from the body’s natural defences, but once the bacteria are remov…
InSite Vision Files IND For ISV-101 With The U.S. Food And Drug Administration For The Treatment Of Dry Eye Disease
InSite Vision Incorporated (OTCBB:INSV) announced that it has filed an Investigational New Drug (IND) application for ISV-101 with the U.S. Food and Drug Administration (FDA). ISV-101 is InSite Vision’s novel compound being developed to treat dry eye d…
Study Evaluates Prevalence Of Age-Related Macular Degeneration In The United States
An estimated 6.5 percent of Americans age 40 and older have the eye disease age-related macular degeneration, a lower rate than was reported 15 years ago, according to a report in the January issue of Archives of Ophthalmology, one of the JAMA/Archives…
Implant Appears Effective For Treating Inflammatory Disease Within The Eye
An implant that releases the medication dexamethasone within the eye appears safe and effective for the treatment of some types of uveitis (swelling and inflammation in the eye’s middle layer), according to a report posted online today that will appear…
Bottle Rockets Can Cause Serious Eye Injuries In Children
Bottle rockets can cause significant eye injuries in children, often leading to permanent loss of vision, according to a report posted online today that will appear in the May print issue of Archives of Ophthalmology, one of the JAMA/Archives journals…
Richard L. Abbott, MD Begins Term As President Of American Academy Of Ophthalmology
Richard L. Abbott, MD became the new president of the American Academy of Ophthalmology on January 1, 2011, taking over from departing President Randy Johnston, MD. Dr. Abbott currently serves as the Thomas W. Boyden health sciences clinical professor …
Top Eye Specialist For PSA’s Offshore Refresher Conference, Australia
Leading eye specialist Dr Peter van Wijngaarden will be one of the faculty of expert speakers at the 2011 PSA Offshore Refresher Conference this year. Dr Peter van Wijngaarden, who was one of the most popular presenters at PAC10 in Melbourne last year…
Lucentis(R) (Ranibizumab) Launched For Vision Loss Due To Diabetic Macular Oedema, A Serious And Common Complication Of Diabetes
Novartis Pharmaceuticals UK Ltd announced that Lucentis® (ranibizumab) has launched in the UK for the treatment of visual impairment due to diabetes, specifically diabetic macular oedema (DMO). This offers fresh hope for people with this serious and c…
6.5% Of Over 40s Have AMD In USA, Versus 9.4% 15 Years Ago
The percentage of Americans aged 40+ with AMD (age-related macular degeneration) has dropped to 6.5% in 2005-2008 from 9.4% in 1988-1994, researchers from the University of Wisconsin School of Medicine and Public Health, Madison reported in an article …
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling
InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, has announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce …
Knowing Your Risks Can Stop The Sneak Thief Of Sight
Glaucoma is a silent illness; most people have no early symptoms and do not notice as their peripheral vision diminishes or blind spots occur. The disease affects more than 2.3 million Americans age 40 and older. Another 2 million do not know they have…
Earlier, More Accurate Detection Of Glaucoma
Cumbersome glaucoma tests that require a visit to the ophthalmologist could soon be history thanks to a home test developed by a UA engineer. The self-test instrument has been designed in Eniko Enikov’s lab at the UA College of Engineering. Gone are th…
Glaucoma Research Foundation Announces New Evidence For The Cause Of Vision Loss In Glaucoma
January is National Glaucoma Awareness Month and the Glaucoma Research Foundation today announced that novel new findings about the underlying cause of glaucoma have been published in the Proceedings of the National Academy of Sciences (Early Edition a…
Alkeus Pharmaceuticals Licenses Novel Ophthalmologic Therapies From Columbia University With Applications In Dry-AMD And Stargardt’s Disease
Alkeus Pharmaceuticals and Columbia University announced today that they have entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerati…
Advanced Cell Technology Receives FDA Clearance For Clinical Trials Using Embryonic Stem Cells To Treat Age-Related Macular Degeneration
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to treat Dry Age-Related M…
Anti-Bacterial Effects Of Impregnating Plastics With Carbon Dioxide
Everyone has heard that carbon dioxide is responsible for global warming. But the gas also has some positive characteristics. Researchers are now impregnating plastics with compressed CO2 in a process that could lead to new applications ranging from co…